WASHINGTON, DC, August 5, 2014 – Gentag, Inc. is pleased to announce that it has been granted additional allowances for its patents in Europe, which will greatly enhance the company’s already significant intellectual property holdings of near field communication (NFC) sensor technologies related to wearable biosensors, body-area-networks (BAN), sensor diagnostics and advanced geolocation.

Gentag’s patents address the uses of disposable diagnostic NFC devices, including skin patches and associated readers in cell phones, and will issue in thirty countries including Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Germany, Estonia, Finland, France, Greece, Hungary, Ireland, Iceland, Italy, Liechtenstein, Lithuania, Luxembourg, Monaco, Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia, Spain, Switzerland, Turkey and the United Kingdom.

With the Gentag technology, it becomes possible to integrate ultrathin battery-less wireless sensors into disposable skin patches for medical and consumer market applications such as fever monitoring, painless diabetes monitoring, drug delivery and obesity monitoring. Gentag’s core suite of patented technologies covers advanced geolocation; environmental genomics, including NFC immunoassays; NFC diagnostic skin patches; and BAN sensor networks. Its first wearables patent was filed in 1997.

About Gentag

Gentag is pioneering the use of disposable, ultrathin wearable biosensors that can be read with NFC-enabled devices, which will make healthcare and consumer diagnostics more affordable and accessible to all worldwide. The company’s groundbreaking work will revolutionize not only medical applications, but also location-based services and the detection of environmental threats in food, homes and workplaces everywhere.

Gentag’s powerful IP and partnerships are at work for a smarter, more connected world.

For more information, visit http://3.236.161.21/ and follow Gentag on Twitter (@gentagInc).